Saturday, 31 October 2026European Markets

OREGE Stock Went Down By Over 9% So Far Today

Loading stream...

orege, a french manufacturer of municipal and industrial sludge treatments, experienced an alarming 9.81% fall to eur0.57 on tuesday - reflecting france's cac 40 index's dip of 1.35% towards eur7,220.92, signalling an overall downward market trend.

orege's recent decline follows a period of underperformance

with shares closing at eur0.63 on thursday - 22.93% below its 52-week high of eur0.82. this suggests a bearish outlook on orege.

decreased demand for orege's shares

with orege's share price decreasing, its trading volume correspondingly dropped significantly below its average volume of 225,080; this indicates decreased demand for its shares.

falling share prices and its reflection on the financial health

orege's falling share prices should not be taken as the sole indicator of its financial health; over the past year it declared a loss, with ttm earnings per share (eps) falling to eur-0.12. such a negative figure reflects more spending than earnings - making the company less desirable among confident investors.

investor caution amid broader stock market instability

as investors remain wary of orege and its performance amid broader stock market instability, investors are exercising caution. orege, an eren groupe sa subsidiary, may need to review its strategic activity and increase shareholder trust in order to revitalize future stock performance.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com